Literature DB >> 15863451

Cytoplasmic fragmentation in activated eggs occurs in the cytokinetic phase of the cell cycle, in lieu of normal cytokinesis, and in response to cytoskeletal disorder.

Mina Alikani1, Tim Schimmel, Steen M Willadsen.   

Abstract

The timing of cytoplasmic fragmentation in relation to the cell cycle was studied in mature oocytes and early cleavage stages using mouse oocytes and embryos as experimental models. The central approach was to remove the nuclear apparatus, in whole or in part, from non-activated and activated oocytes and early embryos, and follow their response during subsequent culture in vitro. Oocytes arrested in metaphase of the second meiotic division did not fragment following complete removal of the meiotic apparatus, provided they were not subsequently activated. Exposure of spindle-chromosome-complex-depleted oocytes to activation conditions immediately after enucleation led to fragmentation, although not until control embryos entered first mitosis. Delaying activation until 24 h post-enucleation led to earlier fragmentation. Enucleation of normally fertilized or artificially activated oocytes after emission of the second polar body also led to fragmentation coinciding with the first mitosis in nucleated control embryos. However, if artificially activated oocytes were prevented from completing second meiosis, by exposure to cytochalasin, and then enucleated, this universal wave of fragmentation was preceded in some cytoplasts by limited fragmentation after just a few hours in culture, and coinciding with completion of meiosis II in nucleated oocytes. Fragmentation also occurred in the second mitotic cell cycle, but it was limited to blastomeres of fertilized oocytes that were enucleated in late interphase. These results indicate that fragmentation in oocytes and early embryos, though seemingly uncoordinated, is a precisely timed event that occurs only in mitotically active cells, during the cytokinetic phase of the cell cycle, in lieu of normal cytokinesis, and in response to altered cytoskeletal organization.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15863451     DOI: 10.1093/molehr/gah171

Source DB:  PubMed          Journal:  Mol Hum Reprod        ISSN: 1360-9947            Impact factor:   4.025


  6 in total

1.  Polar body transfer restores the developmental potential of oocytes to blastocyst stage in a case of repeated embryo fragmentation.

Authors:  Shuo-Ping Zhang; Chang-Fu Lu; Fei Gong; Ping-Yuan Xie; Liang Hu; Shun-Ji Zhang; Guang-Xiu Lu; Ge Lin
Journal:  J Assist Reprod Genet       Date:  2017-02-11       Impact factor: 3.412

Review 2.  Nonviable human pre-implantation embryos as a source of stem cells for research and potential therapy.

Authors:  Mina Alikani; Santiago Munné
Journal:  Stem Cell Rev       Date:  2005-12       Impact factor: 5.739

3.  Oocytes from female mice on MF1 genetic background are not suitable for assisted reproduction†.

Authors:  Yasushiro Yamauchi; Anna Ajduk; Monika A Ward
Journal:  Biol Reprod       Date:  2020-03-13       Impact factor: 4.285

4.  Mammalian Emi2 mediates cytostatic arrest and transduces the signal for meiotic exit via Cdc20.

Authors:  Shisako Shoji; Naoko Yoshida; Manami Amanai; Maki Ohgishi; Tomoyuki Fukui; Satoko Fujimoto; Yoshikazu Nakano; Eriko Kajikawa; Anthony C F Perry
Journal:  EMBO J       Date:  2006-02-02       Impact factor: 11.598

5.  Hesperidin improves the follicular development in 3D culture of isolated preantral ovarian follicles of mice.

Authors:  Hamed Shoorei; Majid Banimohammad; Maziar M Kebria; Mohammad Afshar; Mohammad Mh Taheri; Majid Shokoohi; Mohammad Sg Farashah; Mina Eftekharzadeh; Omid Akhiani; Robert Gaspar; Hamidreza Pazoki-Toroudi
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-19

6.  Developmental dynamics of cloned Mexican bighorn sheep embryos using morphological quality standards.

Authors:  Sarahí Hernández Martínez; José E Hernández Pichardo; José R Vazquez Avendaño; Demetrio Alonso Ambríz García; María Del Carmen Navarro Maldonado
Journal:  Vet Med Sci       Date:  2020-01-29
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.